Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Veru Inc VERU

Consumer Defensive Household & Personal Products
Veru Inc. is a biopharmaceutical company. The Company is focused on developing medicines for the for the treatment of hospitalized COVID-19 patients at high risk for acute respiratory distress syndrome (ARDS) and other viral-related ARDS and for the management of breast and prostate cancers. The Company offers two FDA approved products within its sexual health program, including ENTADFI... see more

Recent & Breaking News (NDAQ:VERU)

Veru Announces Meta-analysis of Body Composition Data from Older Patients with Obesity which Supports Potential for Enobosarm to Optimize Weight Loss at ObesityWeek

GlobeNewswire November 5, 2024

Veru to Present at ObesityWeek: Meta-Analysis of 4 Previous Randomized Clinical Trials that Support the Potential of Enobosarm to Optimize Weight Loss

GlobeNewswire October 21, 2024

Veru to Deliver Keynote Presentation on the Scientific Support for Enobosarm in Combination with GLP-1 Receptor Agonist to Preserve Muscle for Higher Quality Weight Loss at the 4th Edition of the World Obesity and Weight Management Congress

GlobeNewswire October 16, 2024

Veru to Present at the 2024 Cantor Global Healthcare Conference

GlobeNewswire September 11, 2024

Veru Reaches Full Enrollment for Phase 2b QUALITY Clinical Study of Enobosarm for Obesity and Reports Fiscal 2024 Third Quarter Financial Results

GlobeNewswire August 8, 2024

Veru to Report Fiscal 2024 Third Quarter Financial Results on August 8, 2024

GlobeNewswire August 1, 2024

Veru to Participate in the BTIG Virtual Biotechnology Conference

GlobeNewswire July 29, 2024

Veru to Participate in the Leerink Therapeutics Forum: I&I and Metabolism

GlobeNewswire July 2, 2024

Veru Announces Safety and Body Composition Data from Two Late-Breaker Presentations at the American Diabetes Association's 84th Scientific Sessions

GlobeNewswire June 24, 2024

Veru Adjourns 2024 Annual Meeting of Shareholders to June 27, 2024

GlobeNewswire June 18, 2024

Veru Reminds Shareholders to Vote in Advance of Tomorrow's Deadline for 2024 Annual Meeting of Shareholders

GlobeNewswire June 17, 2024

Veru to Present at the American Diabetes Association's 84th Scientific Sessions

GlobeNewswire June 10, 2024

Veru to Present at the Jefferies Global Healthcare Conference

GlobeNewswire May 22, 2024

Veru Announces Steven B. Heymsfield M.D. as the Principal Investigator for its Enobosarm Phase 2b Clinical Trial for High Quality Weight Loss

GlobeNewswire May 15, 2024

Veru Announces Mitchell Steiner as Keynote Speaker at Biomed Israel 2024: The 22nd National Life Science & Technology Week

GlobeNewswire May 14, 2024

Veru Reports Fiscal 2024 Second Quarter Financial Results and Progress of its Enobosarm High Quality Weight Loss Clinical Program

GlobeNewswire May 8, 2024

Veru to Present at the GLP-1 Based Therapeutics Summit

GlobeNewswire May 2, 2024

Veru to Report Fiscal 2024 Second Quarter Financial Results on May 8, 2024

GlobeNewswire May 1, 2024

Veru Enrolls First Patients in Phase 2b Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss

GlobeNewswire April 30, 2024

Veru to Present at the American Association of Clinical Endocrinology (AACE) 2024 Annual Meeting on May 9-11

GlobeNewswire April 25, 2024